Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Angioimmunoblastic T-cell Lymphoma
Interventions
DRUG

mitoxantrone liposome 16 and azacitidine

The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).

DRUG

mitoxantrone liposome 18 and azacitidine

The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).

DRUG

mitoxantrone liposome 20 and azacitidine

The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).

Trial Locations (1)

430079

RECRUITING

Hubei Cancer Hospital, Wuhan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Beijing Xisike Clinical Oncology Research Foundation

UNKNOWN

collaborator

CSPC Pharmaceutical Group

UNKNOWN

lead

Huijing Wu

OTHER

NCT06224842 - Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL | Biotech Hunter | Biotech Hunter